Eric Quéméneur
Chief Tech/Sci/R&D Officer bij TRANSGENE
Profiel
Eric Quéméneur is currently the Director & EVP-Research & Development at ElsaLys Biotech SAS and the Chief Scientific Officer & Executive VP at Transgene SA. Previously, he worked as the Director-Research Programs at Comité de l’énergie Atomique from 1990 to 2014.
Dr. Quéméneur holds a doctorate degree from Université Claude Bernard Lyon 1 and an undergraduate degree from Institut National des Sciences Appliquées de Lyon, which he obtained in 1986.
Actieve functies van Eric Quéméneur
Bedrijven | Functie | Begin |
---|---|---|
TRANSGENE | Chief Tech/Sci/R&D Officer | 01-09-2014 |
ELSALYS BIOTECH | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Eric Quéméneur
Bedrijven | Functie | Einde |
---|---|---|
Comité de l’énergie Atomique | Corporate Officer/Principal | 01-09-2014 |
Opleiding van Eric Quéméneur
Université Claude Bernard Lyon 1 | Doctorate Degree |
Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
TRANSGENE | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Comité de l’énergie Atomique | Government |
ElsaLys Biotech SAS
ElsaLys Biotech SAS Pharmaceuticals: MajorHealth Technology ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France. | Health Technology |